Your browser doesn't support javascript.
loading
Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study.
Dunn, Sarah; Brocklebank, Victoria; Bryant, Andrew; Carnell, Sonya; Chadwick, Thomas J; Johnson, Sally; Kavanagh, David; Lecouturier, Jan; Malina, Michal; Moloney, Eoin; Oluboyede, Yemi; Weetman, Christopher; Wong, Edwin Kwan Soon; Woodward, Len; Sheerin, Neil.
Afiliación
  • Dunn S; Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK sarah.dunn2@ncl.ac.uk.
  • Brocklebank V; National Renal Complement Therapeutics Centre, Newcastle University, Newcastle upon Tyne, UK.
  • Bryant A; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Carnell S; Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.
  • Chadwick TJ; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Johnson S; National Renal Complement Therapeutics Centre, Newcastle University, Newcastle upon Tyne, UK.
  • Kavanagh D; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Lecouturier J; National Renal Complement Therapeutics Centre, Newcastle University, Newcastle upon Tyne, UK.
  • Malina M; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Moloney E; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Oluboyede Y; National Renal Complement Therapeutics Centre, Newcastle University, Newcastle upon Tyne, UK.
  • Weetman C; Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Wong EKS; Health Economics, Optimax Access, Newcastle upon Tyne, UK.
  • Woodward L; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Sheerin N; Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.
BMJ Open ; 12(9): e054536, 2022 09 19.
Article en En | MEDLINE | ID: mdl-36123058
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Hemolítico Urémico Atípico Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Ethics Límite: Humans Idioma: En Revista: BMJ Open Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Hemolítico Urémico Atípico Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Aspecto: Ethics Límite: Humans Idioma: En Revista: BMJ Open Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido